Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Relatorilant em combinação com Nab-Paclitaxel em câncer de ovário avançado, resistente à platina, epitelial de alto grau, peritoneal primário ou de trompas de falópio

24 de setembro de 2026 atualizado por: Corcept Therapeutics

Um estudo de Fase 3 de Relatorilant em combinação com monoterapia de Nab-Paclitaxel versus Nab-Paclitaxel em câncer avançado, resistente à platina, epitelial de alto grau ovariano, peritoneal primário ou de trompas de falópio (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Visão geral do estudo

Descrição detalhada

As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel.

Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.

Tipo de estudo

Intervencional

Inscrição (Real)

381

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1280AEB
        • Site 393
      • Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina, C1426ANZ
        • Site 381
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentina, X5004FHP
        • Site 415
      • Córdoba, Córdoba Province, Argentina, X5008 HHW
        • Site 401
      • Córdoba, Córdoba Province, Argentina, X5016
        • Site 395
    • Mendoza Province
      • Mendoza, Mendoza Province, Argentina, M5500AYB
        • Site 404
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Site 391
      • Rosario, Santa Fe Province, Argentina, S2000KDS
        • Site 412
    • New South Wales
      • St Leonards, New South Wales, Austrália, 2065
        • Site 426
    • Queensland
      • Benowa, Queensland, Austrália, 4217
        • Site 417
    • Victoria
      • Melbourne, Victoria, Austrália, 3000
        • Site 414
      • Melbourne, Victoria, Austrália, 3128
        • Site 419
      • Porto Alegre, Brasil, 90035-001
        • Site 421
    • Brasília - DF
      • Brasília, Brasília - DF, Brasil, 70297-400
        • Site 424
    • Ceará
      • Fortaleza, Ceará, Brasil, 60170-170
        • Site 382
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 41950-640
        • Site 384
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasil, 30210-040
        • Site 383
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasil, 59062-000
        • Site 390
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brasil, 22250-905
        • Site 380
    • São Paulo
      • São Paulo, São Paulo, Brasil, 01321001
        • Site 376
      • São Paulo, São Paulo, Brasil, 01327-001
        • Site 389
      • São Paulo, São Paulo, Brasil, 01409-002
        • Site 413
      • São Paulo, São Paulo, Brasil, 01509-900
        • Site 374
      • São Paulo, São Paulo, Brasil, 01509010
        • Site 001
      • Aalst, Bélgica, 9300
        • Site 328
      • Brussels, Bélgica, B- 1200
        • Site 109
      • Charleroi, Bélgica, 6000
        • Site 326
      • Hasselt, Bélgica, 3500
        • Site 325
      • Leuven, Bélgica, 3000
        • Site 108
      • Liège, Bélgica, B-4000
        • Site 327
    • Ontario
      • Toronto, Ontario, Canadá, M4N 3M5
        • Site 117
    • Quebec
      • Montreal, Quebec, Canadá, H4A 3J1
        • Site 273
      • Gyeonggi-do, Coréia do Sul, 10408
        • Site 397
      • Seoul, Coréia do Sul, 03080
        • Site 399
      • Seoul, Coréia do Sul, 03722
        • Site 398
      • Seoul, Coréia do Sul, 05505
        • Site 403
      • Seoul, Coréia do Sul, 06273
        • Site 400
      • Seoul, Coréia do Sul, 06351
        • Site 396
      • Seoul, Coréia do Sul, 08308
        • Site 402
      • Seoul, Coréia do Sul, 42601
        • Site 409
      • Badalona, Espanha, 08916
        • Site 349
      • San Sebastián, Espanha, 20014
        • Site 311
      • Valencia, Espanha, 46026
        • Site 330
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85016
        • Site 318
      • Tucson, Arizona, Estados Unidos, 85719
        • Site 277
    • California
      • Irvine, California, Estados Unidos, 92618
        • Site 350
      • La Jolla, California, Estados Unidos, 92093
        • Site 364
      • Palo Alto, California, Estados Unidos, 94304
        • Site 150
      • San Francisco, California, Estados Unidos, 94109
        • Site 278
      • San Francisco, California, Estados Unidos, 94143
        • Site 014
      • Solvang, California, Estados Unidos, 93463
        • Site 316
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Site 032
    • Florida
      • Miami Beach, Florida, Estados Unidos, 33140
        • Site 335
      • Weston, Florida, Estados Unidos, 33331
        • Site 042
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Site 009
      • Atlanta, Georgia, Estados Unidos, 30342
        • Site 272
      • Gainesville, Georgia, Estados Unidos, 30548
        • Site 372
      • Savannah, Georgia, Estados Unidos, 31405
        • Site 291
    • Illinois
      • Evanston, Illinois, Estados Unidos, 60201
        • Site 315
      • Hinsdale, Illinois, Estados Unidos, 60521
        • Site 314
      • Urbana, Illinois, Estados Unidos, 61801
        • Site 346
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Site 339
    • Kansas
      • Overland Park, Kansas, Estados Unidos, 66211
        • Site 200
      • Overland Park, Kansas, Estados Unidos, 66211
        • Site 334
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40241
        • Site 279
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Site 128
    • New Jersey
      • New Brunswick, New Jersey, Estados Unidos, 08901
        • Site 288
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87131
        • Site 292
    • New York
      • Flushing, New York, Estados Unidos, 11355
        • Site 275
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45242
        • Site 298
      • Cincinnati, Ohio, Estados Unidos, 45459
        • Site 304
    • Oregon
      • Portland, Oregon, Estados Unidos, 97210
        • Site 280
      • Portland, Oregon, Estados Unidos, 97213
        • Site 317
      • Portland, Oregon, Estados Unidos, 97239
        • Site 049
    • Pennsylvania
      • Bethlehem, Pennsylvania, Estados Unidos, 18015
        • Site 337
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • Site 127
    • South Dakota
      • Rapid City, South Dakota, Estados Unidos, 57701
        • Site 276
    • Tennessee
      • Germantown, Tennessee, Estados Unidos, 38138
        • Site 368
      • Nashville, Tennessee, Estados Unidos, 37203
        • Site 281
    • Texas
      • Austin, Texas, Estados Unidos, 78731
        • Site 229
      • Bedford, Texas, Estados Unidos, 76022
        • Site 312
      • Fort Worth, Texas, Estados Unidos, 76104
        • Site 297
      • San Antonio, Texas, Estados Unidos, 78240
        • Site 392
      • The Woodlands, Texas, Estados Unidos, 77380
        • Site 301
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23502
        • Site 300
      • Richmond, Virginia, Estados Unidos, 23298
        • Site 365
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Site 121
      • Lille, França, 59020
        • Site 306
      • Montpellier, França, 34298
        • Site 347
      • Nancy, França, 54100
        • Site 307
      • Nice, França, 06189
        • Site 310
      • Paris, França, 75015
        • Site 289
      • Plérin, França, 22190
        • Site 323
      • Budapest, Hungria, 1122
        • Site 322
      • Debrecen, Hungria, 4032
        • Site 290
      • Győr, Hungria, 9024
        • Site 348
      • Haifa, Israel, 3436212
        • Site 309
      • Jerusalem, Israel, 911201
        • Site 080
      • Tel Aviv, Israel, 6423906
        • Site 203
      • Catania, Itália, 95126
        • Site 321
      • Legnago, Itália, 37045
        • Site 320
      • Milan, Itália, 20141
        • Site 122
      • Pavia, Itália, 27100
        • Site 295
      • Roma, Itália, 161
        • Site 161
      • Rome, Itália, 00168
        • Site 124
      • Torino, Itália, 10128
        • Site 293
      • Treviso, Itália, 31100
        • Site 319
      • Gdynia, Polônia, 81-519
        • Site 341
      • Poznan, Polônia, 61-886
        • Site 331
      • Siedlce, Polônia, 08-110
        • Site 329
      • Cheltenham, Reino Unido, GL53 7AN
        • Site 366
      • London, Reino Unido, NW1 2PG
        • Site 055
      • Manchester, Reino Unido, M20 4BX
        • Site 344
      • Northwood, Reino Unido, HA6 2RN
        • Site 345
    • East Sussex
      • Brighton, East Sussex, Reino Unido, BN2 1ES
        • Site 367
    • Somerset
      • Taunton, Somerset, Reino Unido, TA1 5DA
        • Site 351

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures.
  • Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
  • Patients must have platinum-resistant disease (defined as RECIST v1.1 defined progression <6 months from completion of a platinum-containing therapy).
  • Must consent to provide archival tumor-tissue block or slides. Patients may consent to an optional tumor biopsy if archival tumor is unavailable.
  • Has a life expectancy of ≥3 months.
  • At least one lesion that meets the definition of measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Able to comply with protocol requirements.
  • Able to swallow and retain oral medication and does not have uncontrolled emesis.
  • Received at least 1 but ≤3 lines of prior systemic anticancer therapy and at least 1 prior line of platinum therapy and prior treatment with bevacizumab is required.
  • Has adequate organ function meeting the following laboratory-test criteria: Absolute neutrophil count (ANC) ≥1500 cells/mm^3, Platelet count ≥100,000/mm^3, Hemoglobin ≥9 g/dL, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases, Total bilirubin ≤1.5 × ULN, and Albumin ≥3 g/dL, and creatinine clearance >40 mL/min/1.73 m^2 (measured or estimated).
  • Negative pregnancy test for patients of childbearing potential; patients of childbearing potential must agree to use highly effective contraceptive method(s); hormonal contraceptives are not allowed.
  • Coronavirus disease (COVID-19) approved vaccines are accepted concomitant medications when recommended by the Investigator.

Exclusion Criteria:

  • Has clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to ≤Grade 1 prior to randomization.
  • Has had any major surgery within 4 weeks prior to randomization.
  • Has low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.
  • Has primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤1 month of the last dose of first-line platinum-containing chemotherapy.
  • Has not received prior bevacizumab treatment.
  • Has been treated with the following prior to randomization: chemotherapy, immunotherapy, investigational agent treatments for disease under study within 28 days before first dose of study drug, radiotherapy not completed at least 2 weeks prior to first dose of study drug, hormonal anticancer therapies within 7 days of first dose of study drug, and systemic, inhaled, or prescription strength topical corticosteroids within 21 days of first dose of study drug.
  • Has received wide-field radiation to more than 25% of marrow-bearing areas.
  • Has toxicities of prior therapies that have not resolved by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, ≤Grade 1.
  • Requires treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses.
  • Has a history of severe hypersensitivity or severe reaction to any of the study drugs.
  • Is receiving concurrent treatment with mifepristone or other glucocorticoid receptor (GR) modulators.
  • Has peripheral neuropathy from any cause >Grade 1.
  • Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 1 month after the last dose of relacorilant, or 6 months after the last dose of nab-paclitaxel whichever is the longest.
  • Has clinically significant uncontrolled condition(s) or condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation.
  • Has current chronic/active infection with human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus.
  • Has any untreated or symptomatic central nervous system (CNS) metastases.
  • Patients with a history of other malignancy within 3 years prior to randomization.
  • Is taking a concomitant medication that is a strong cytochrome P450 (CYP)3A inhibitor or strong CYP3A inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
  • Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
  • Has received a live vaccine within 30 days prior to the study start date.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2

Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.

Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.

Outros nomes:
  • Lifyorli

Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Comparador Ativo: Nab-paclitaxel 100 mg/m^2

Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.

Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Prazo: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions.

Up to 20 months
Overall Survival
Prazo: Up to 32 months

Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates.

Up to 32 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
PFS as Assessed by the Investigator
Prazo: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) by RECIST v1.1, or death due to any cause, whichever occurs first.

Up to 20 months
Objective Response as Assessed by the Investigator
Prazo: Up to 20 months

Objective response was assessed as the proportion of patients with measurable disease at baseline who attained complete response (CR) or partial response (PR). Confirmation of the response was not required for this outcome measure per RECIST v1.1 criteria for randomized controlled clinical trials. Responses were assessed by imaging, using RECIST v1.1 criteria for target lesions: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Up to 20 months
Best Overall Response as Assessed by the Investigator
Prazo: Up to 20 months

Best overall response was assessed as the proportion of patients with at least 1 post Baseline scan who attained CR, PR, stable disease (SD), or PD as best response by RECIST v1.1.

Up to 20 months
Duration of Confirmed Responses as Assessed by the Investigator
Prazo: From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)

The median duration of response is presented for confirmed responses (CR or PR) per RECIST v1.1. Duration of response was from the first documented and confirmed response to the first objectively documented PD as assessed by the Investigator, or death due to any cause, whichever occurs first.

From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
Clinical Benefit Rate at 24 Weeks as Assessed by BICR and the Investigator
Prazo: 24 weeks

Clinical benefit rate was assessed as the proportion of patients who attained CR, PR, or stable disease (SD) for 24 weeks per RECIST v1.1 as assessed by BICR and as assessed by the Investigator.

24 weeks
Cancer Antigen (CA)-125 Response
Prazo: Up to 24 months

CA-125 response was assessed per Gynecologic Cancer Intergroup (GCIG) criteria defined as ≥50% reduction in CA-125 from a pretreatment sample and maintained for ≥28 days in patients with a pretreatment sample that is at least twice the upper limit of the reference range within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level fell to within the reference range were classified as CA-125 complete responders.

Up to 24 months
Combined Overall Response Rate by RECIST v1.1 and CA-125 Defined by GCIG Criteria
Prazo: Up to 15 months

Combined response was assessed as the proportion of patients with tumor response per RECIST v1.1 assessed by the investigator and for CA-125 response per GCIG criteria.

Up to 15 months
Number of Patients With One or More Adverse Events
Prazo: Up to 22 months
Up to 22 months
Number of Patients Who Discontinued the Study Treatment Due to an Adverse Event
Prazo: Up to 25 months
Up to 25 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Adrian Jubb, MBChB, PhD, FRCPath, Corcept Therapeutics

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de junho de 2022

Conclusão Primária (Real)

31 de março de 2025

Conclusão do estudo (Estimado)

1 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

4 de fevereiro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de fevereiro de 2022

Primeira postagem (Real)

25 de fevereiro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CORT125134-556
  • GOG-3073 (Outro identificador: Gynecologic Oncology Group)
  • ROSELLA Study 556 (Outro identificador: Corcept Therapeutics)
  • ENGOT-OV72 (Outro identificador: European Network of Gynaecological Oncological Trial Groups)
  • APGOT-Ov10 (Outro identificador: Asia-Pacific Gynecologic Oncology Trials Group)
  • LACOG 0223 (Outro identificador: Latin American Cooperative Oncology Group)
  • ANZGOG2221/2023 (Outro identificador: Australia New Zealand Gynaecological Oncology Group)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever